 |
|
New treatment approach promising for lymphoma patients in the developing world
July 07, 2008ESMO Conference Lugano, July 3-6, 2008, Lugano, Switzerland
Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.
At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, a group headed by Prof. Hamdy Azim from Cairo University reports that giving these patients chemotherapy every 2 weeks, rather than every 3 weeks as usual, improved treatment outcomes.
The standard regimen in this case is called CHOP (chemotherapy regime), which is given every 3 weeks. In the developed world, CHOP is administered in combination with an antibody therapy called rituximab.
But many patients in developing countries, including Egypt where this study was conducted, cannot afford this treatment, so they are offered CHOP alone.
"We hypothesized that if CHOP or a CHOP-like regimen was given every two weeks instead of three, a superior outcome could be achieved," says Dr. Hatem A. Azim Jr, who presented these results at ECLU.
To see if this was the case, they analyzed five trials that compared CHOP to regimens given every two weeks. Using two statistical analyses, they showed that regimens every two weeks had superior response rate, disease-free and overall survival; however in one method, the response rate analysis did not reach statistical significance.
"We believe that this work could provide good evidence to support the use of the 2-weekly regimen," Dr. Azim Jr said. One issue that remains to be assessed is how well patients tolerate the more intense treatment, he noted.
"Patients on the 2-weekly regimens have to receive injections with 'growth factors' to ensure that severe toxicities to the white blood cells do not occur," he said. "Even so, the cost of these injections per cycle is much lower than that of rituximab. The preliminary results are encouraging in providing patients who cannot afford the cost of rituximab, a better alternative than CHOP."
European Society for Medical Oncology
The standard regimen in this case is called CHOP (chemotherapy regime), which is given every 3 weeks. In the developed world, CHOP is administered in combination with an antibody therapy called rituximab.
But many patients in developing countries, including Egypt where this study was conducted, cannot afford this treatment, so they are offered CHOP alone.
"We hypothesized that if CHOP or a CHOP-like regimen was given every two weeks instead of three, a superior outcome could be achieved," says Dr. Hatem A. Azim Jr, who presented these results at ECLU.
To see if this was the case, they analyzed five trials that compared CHOP to regimens given every two weeks. Using two statistical analyses, they showed that regimens every two weeks had superior response rate, disease-free and overall survival; however in one method, the response rate analysis did not reach statistical significance.
"We believe that this work could provide good evidence to support the use of the 2-weekly regimen," Dr. Azim Jr said. One issue that remains to be assessed is how well patients tolerate the more intense treatment, he noted.
"Patients on the 2-weekly regimens have to receive injections with 'growth factors' to ensure that severe toxicities to the white blood cells do not occur," he said. "Even so, the cost of these injections per cycle is much lower than that of rituximab. The preliminary results are encouraging in providing patients who cannot afford the cost of rituximab, a better alternative than CHOP."
European Society for Medical Oncology
Lymphoma Current Events and Lymphoma News RSSHodgkin lymphoma -- new characteristics discovered
Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern.
How to differentiate abdominal tuberculosis from lymphomas?
The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes.
NC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.
Researchers discover how rheumatoid arthritis causes bone loss
Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry.
Duke chemists synthesize promising anti-cancer product
Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.
Children's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
Researchers find cancer-inhibiting compound under the sea
University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.
Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.
More Lymphoma Current Events and Lymphoma News Articles
 | Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler "Adler's professional background and experience as a lymphoma survivor make her the perfect person to write this book. The author's explanations are a gentle guide and a thorough introduction to the basics that give us the confidence to handle decisions relating to treatments and other aspects of lymphoma." -- Anne Atkinson, non-Hodgkin lymphoma and Hodgkin disease survivor and coordinator of the... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, Jodi Garrett, William D. Jansen This book deals with lymphoma from a doctor's and a caregiver's... |
 | An Illustrated Guide to Skin Lymphoma by Lorenzo Cerroni, Kevin Gatter, Helmut Kerl Skin lymphomas are relatively rare. They may arise in the skin itself and as a by-product of HIV infection, or may arise elsewhere as a result of Hodgkin's disease, B cell lymphomas or leukaemia. Whatever the cause, they can easily be overlooked as psoriasis or dermatitis. Diagnosis of skin lymphoma is difficult and making the wrong diagnosis can prove fatal. Consequently, those in... |
 | Non-Hodgkin's Lymphomas: A Self-Study Program This definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin's lymphomas reflects an international, multidisciplinary approach to the topic. The editors and contributors have backgrounds in medical and radiation oncology, pathology, and molecular biology. The text offers complete coverage of the subject matter, with a blend of basic science and clinical... |
 | Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston Prior to publication of this resource guide, no book on the market targeted the non-Hodgkin's lymphoma survivor's need for understandable information. While there are medical texts on the non-Hodgkin's lymphomas as well as inspirational first-person accounts from survivors of related cancers such as leukemia, between these two sources of information existed a considerable information gap. In... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, MD - Jodi Garrett, RN - William Jansen by MD - Jodi Garrett, RN - William Jansen Peter Holman JC#1 - Brand New/Selead - What is lymphoma? What causes lymphoma? What are the options available for the treatment of lymphoma? What are the common reactions to being diagnosed with lymphoma? Thank You For... |
 | Image-Guided Radiotherapy and Functional Imaging in Modern Lymphoma Management An ideal text for radiation oncologists, hematologist-oncologists, and radiologists, Image-Guided Radiotherapy and Functional Imaging in Modern Lymphoma Management is the foremost source for information on the increasingly important subject of image guided radiation therapy (IGRT) and its crucial role in the clinical evolution of high-precision ionizing beam therapy. An understanding of IGRT... |
| UNDERSTANDING NON-HODGKIN'S LYMPHOMA A GUIDE FOR PATIENTS by LYMPHOMA RESEARCH-FOUNDATION | |
 | Lymphoma: Pathology, Diagnosis and Treatment Major advances have occurred in almost every aspect of the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant developments in imaging of this malignancy have resulted in earlier and more accurate diagnosis. At the same time, advances in therapeutic immunology have led to the... |
| Hodgkin's Disease and Non-Hodgkin's Lymphomas in Adults and Children |
| © 2008 BrightSurf.com |